Renaissance Technologies LLC Buys Shares of 386,955 10x Genomics, Inc. (NASDAQ:TXG)

Renaissance Technologies LLC bought a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 386,955 shares of the company's stock, valued at approximately $5,557,000. Renaissance Technologies LLC owned approximately 0.32% of 10x Genomics as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of TXG. Signaturefd LLC raised its position in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after purchasing an additional 1,452 shares during the period. Blue Trust Inc. raised its holdings in 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after buying an additional 1,299 shares during the period. Sound Income Strategies LLC lifted its stake in 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after buying an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of 10x Genomics in the fourth quarter worth about $52,000. Finally, SRS Capital Advisors Inc. increased its position in shares of 10x Genomics by 817.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock worth $70,000 after acquiring an additional 4,324 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Price Performance

Shares of TXG traded up $0.17 on Thursday, reaching $8.19. 4,193,754 shares of the stock traded hands, compared to its average volume of 3,109,794. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -5.39 and a beta of 2.01. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $29.37. The stock's 50-day moving average price is $9.63 and its 200-day moving average price is $13.27.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities research analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Transactions at 10x Genomics

In related news, Director Alan Mateo acquired 40,000 shares of the stock in a transaction on Friday, February 21st. The stock was purchased at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the transaction, the director now owns 61,691 shares of the company's stock, valued at $687,237.74. The trade was a 184.41 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of the company's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the transaction, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.03% of the company's stock.

Wall Street Analyst Weigh In

TXG has been the topic of several research analyst reports. Citigroup lowered their price objective on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Morgan Stanley dropped their price target on 10x Genomics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Leerink Partners lowered 10x Genomics from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $25.00 to $12.00 in a research report on Thursday, February 13th. Stifel Nicolaus dropped their price target on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group cut their price target on 10x Genomics from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, 10x Genomics currently has an average rating of "Hold" and an average price target of $19.79.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.